[1] Patel N, Bhargava A, Kalra R, et al. Trends in lipid, lipoproteins, and statin use among U.S. adults: impact of 2013 cholesterol guidelines[J]. J Am Coll Cardiol, 2019, 74:2525-2528. [2] Wu X, Gong C, Weinstock J, et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia[J]. Clin Appl Thromb Hemost, 2018, 24: 240S-247S. [3] Stock JK. Update on SAMS: Statin-associated muscle symptoms[J]. Atherosclerosis, 2018, 269:260-261. [4] 吕园, 邱樊, 薛雪, 等. SLCO1B1&ApoE基因多态性检测性能验证[J]. 临床检验杂志, 2017, 11:868-871. [5] Backes JM, Ruisinger JF, Gibson CA, et al. Statin-associated muscle symptoms-managing the highly intolerant[J].J Clin Lipidol, 2017, 11:24-33. [6] Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)[J]. Br J Clin Pharmacol, 2017,83:1176-1184. [7] Ciuculete DM, Bandstein M, Benedict C,et al. A genetic risk score is significantly associated with statin therapy response in the elderly population[J]. Clin Genet, 2017, 91:379-385. [8] SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study[J]. N Engl J Med, 2008,359:789-799. [9] Huebbe P, Rimbach G.Evolution of human apolipoprotein E (ApoE) isoforms: Gene structure, protein function and interaction with dietary factors[J].Ageing Res Rev, 2017, 37:146-161. |